Which treatment is right for you?
PRP is a useful first-line autologous option for mild orthopedic complaints. Wharton's Jelly MSC therapy is a higher-potency intervention with a wider biological footprint — more relevant for established cartilage loss, multi-site disease, or patients who have already plateaued on PRP.
Stem cell therapy is the better answer when:
- Moderate-to-advanced cartilage loss (KL grade 2–3)
- Failed prior PRP courses
- Bilateral or multi-joint disease
- Systemic inflammatory drivers (autoimmune overlap)
PRP (Platelet-Rich Plasma) Injections is the better answer when:
- Early, mild tendinopathy
- Recent acute soft-tissue injury
- Patients wanting an autologous, in-office option
- Budget-limited maintenance between regenerative cycles
What each option actually is
Wharton's Jelly stem cell therapy
Wharton's Jelly mesenchymal stem cell therapy uses neonatal MSCs harvested from ethically donated umbilical cord tissue. The cells are GMP-expanded, characterized for viability and surface markers, then delivered IV and/or by image-guided intra-articular injection. They act through paracrine signalling — releasing exosomes, anti-inflammatory cytokines (IL-10, TGF-β), and growth factors (VEGF, HGF, IGF-1) that modulate immune response and support tissue repair.
PRP (Platelet-Rich Plasma) Injections
PRP is produced by drawing the patient's own blood, centrifuging it to concentrate platelets, and re-injecting that plasma into the target site. The platelets release growth factors (PDGF, TGF-β, VEGF) that recruit local repair cells. PRP contains no living MSCs and no exosome cargo from neonatal tissue — its biological payload is limited by the donor (the patient's own age and inflammation status).
Side-by-side comparison
| Dimension | Stem cell therapy | PRP |
|---|---|---|
| Biological payload | Living MSCs + exosomes + ~30+ cytokines | Platelet-derived growth factors only |
| Cell source | Neonatal Wharton's Jelly (allogeneic, screened) | Autologous adult blood |
| Potency vs donor age | Constant — neonatal donor | Declines with patient age & inflammation |
| Sessions typically needed | 1 program, often single infusion + targeted injections | 2–3 injections per joint per cycle |
| Duration of benefit (reported) | 12–24 months in published cohorts | 6–9 months on average |
| Best for early tendinopathy | Often over-treatment | Strong first-line option |
| Best for KL 2–3 knee OA | Higher-potency option | Diminishing returns |
| Per-procedure cost | Higher upfront, fewer repeats | Lower per session, recurring |
| Recovery downtime | 24–48h | 2–5 days soreness |
| Surgical alternative if failed | Joint replacement still possible | Joint replacement still possible |
What patients actually pay
Stem cell therapy: All-inclusive Wharton's Jelly program in Istanbul typically ranges from €6,500–€14,500 depending on cell count, exosome add-ons and number of joints treated.
PRP: PRP in Western Europe / US runs roughly $600–$1,500 per injection, with 2–3 sessions commonly recommended per joint per year.
Realistic downtime
Stem cell therapy: Most patients resume normal activity within 24–48 hours. Anti-inflammatories are restricted for 10–14 days so the regenerative signalling is not blunted.
PRP: Soreness for 2–5 days. Same NSAID-avoidance window applies. Activity modification for 1–2 weeks for tendon work.
What the published evidence actually says
Both interventions have published peer-reviewed evidence in osteoarthritis. Meta-analyses (Cochrane, AJSM) generally show PRP outperforming hyaluronic acid for mild knee OA, while MSC trials (e.g. Lamo-Espinosa et al., Vega et al.) report improvements in pain and function in moderate OA. Neither is a guaranteed cure; both are regenerative-medicine options that should be selected based on disease stage and prior response.
Common questions when comparing these treatments
Is stem cell therapy better than PRP?
Not universally — it is a different category of intervention. Stem cell therapy delivers a far broader regenerative payload and tends to outperform PRP in moderate-to-advanced osteoarthritis or after PRP has plateaued. For mild tendinopathy or as a maintenance therapy, PRP is often the more proportionate choice.
Can I do PRP and stem cell therapy together?
Yes. Many of our orthopedic patients receive an MSC + exosome program, then use PRP as a lower-cost maintenance booster every 6–12 months.
Why do stem cells last longer than PRP?
PRP releases growth factors over days to weeks. MSCs continue to secrete exosomes and cytokines for weeks, and the immunomodulatory effect can persist for months — translating to a longer functional window in most published cohorts.
How much does each cost in Turkey?
Wharton's Jelly MSC programs at our Istanbul clinic typically start around €6,500 all-inclusive. PRP is often included as part of an orthopedic regenerative program rather than billed separately.